pre-update Archives

Publication

Ammonia Control in Children with Urea Cycle Disorders (UCDs); Phase 2 Comparison of Sodium Phenylbutyrate and Glycerol Phenylbutyrate

Twenty four hour ammonia profiles and correlates of drug effect were examined in a phase…

Certara2011 年 8 月 1 日

知识库

How Can PK/PD Analysis Add Value to Patient Care?

In May 2011, T.J. Smith and B.E. Hillner published an opinion piece in the New…

Certara2011 年 7 月 11 日

知识库

What is Curve Stripping?

The process of curve stripping is used in both compartmental and non-compartmental analysis. Each pharmacokinetic…

Certara2011 年 7 月 6 日

Publication

Pharmacokinetic-pharmacodynamic Disease Progression Model for Effect of Etanercept in Lewis Rats with Collagen-induced Arthritis

The purpose of this study was to develop a pharmacokinetic-pharmacodynamic disease progression (PK/PD/DIS) model to…

Certara2011 年 7 月 1 日

Publication

Clinical Tolerance and Toxicity of Intravenous Baclofen: A Pilot Study in a Canine Model

Assess safety and tolerance of intravenous (IV) baclofen using a dog model. Prospective pharmacokinetic study…

Certara2011 年 7 月 1 日

Publication

Simulation of Clinical Drug-drug Interactions from Hepatocyte CYP3A4 Induction Data and Its Potential Utility in Trial Designs

Rifampin and carbamazepine have been recommended in the U.S. Food and Drug Administration draft drug…

Certara2011 年 7 月 1 日

Publication

Metabolism of [D10]Phenanthrene to Tetraols in Smokers for Potential Lung Cancer Susceptibility Assessment: Comparison of Oral and Inhalation Routes of Administration

Polycyclic aromatic hydrocarbons (PAHs) are believed to be among the causative agents for lung cancer…

Certara2011 年 7 月 1 日

Publication

Prediction of Time-dependent CYP3A4 Drug-drug Interactions by Physiologically-based Pharmacokinetic Modeling: Impact of Inactivation Parameters and Enzyme Turnover

Predicting the magnitude of time-dependent metabolic drug-drug (mDDIs) interactions involving cytochrome P-450 3A4 (CYP3A4) from…

Certara2011 年 6 月 14 日

Publication

Model-based Development of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor

A model-based strategy was used to inform the early clinical development of anacetrapib, a novel…

Certara2011 年 6 月 1 日

Publication

Systems Pharmacology: Bridging Systems Biology and (PK/PD)

Mechanistic PKPD models are now advocated not only by academic and industrial researchers, but also…

Certara2011 年 5 月 11 日

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software

pre-update

Ammonia Control in Children with Urea Cycle Disorders (UCDs); Phase 2 Comparison of Sodium Phenylbutyrate and Glycerol Phenylbutyrate

How Can PK/PD Analysis Add Value to Patient Care?

What is Curve Stripping?

Pharmacokinetic-pharmacodynamic Disease Progression Model for Effect of Etanercept in Lewis Rats with Collagen-induced Arthritis

Clinical Tolerance and Toxicity of Intravenous Baclofen: A Pilot Study in a Canine Model

Simulation of Clinical Drug-drug Interactions from Hepatocyte CYP3A4 Induction Data and Its Potential Utility in Trial Designs

Metabolism of [D10]Phenanthrene to Tetraols in Smokers for Potential Lung Cancer Susceptibility Assessment: Comparison of Oral and Inhalation Routes of Administration

Prediction of Time-dependent CYP3A4 Drug-drug Interactions by Physiologically-based Pharmacokinetic Modeling: Impact of Inactivation Parameters and Enzyme Turnover

Model-based Development of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor

Systems Pharmacology: Bridging Systems Biology and (PK/PD)

订阅时事通讯

快捷链接

解决方案

联系我们